Possibly. Though, since the IC50 value for FTO inhibition is hundreds of times lower than topo2, Zan will be binding to FTO molecules long before it binds to topo2.
Using Zantrene as an anthracene to treat cancer is like using your forehead to hit a nail into wood. You can do it, but you're probably better off getting a hammer (FTO inhibition).
Something for holders to mull over - there is as much clinical validation data for topo2 as there is for FTO. Historical researchers just assumed it was topo2 because FTO wasn't known at the time. My bet is FTO.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-104
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.015(1.03%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.47 | $1.51 | $1.44 | $104.3K | 70.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8452 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 300 | 1 |
View Market Depth
| Last trade - 14.25pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.47 |
Change
-0.015 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.49 | $1.50 | $1.46 | 12453 | ||
| Last updated 14.08pm 27/05/2024 ? | |||||
| RAC (ASX) Chart |